Cover Image
Market Research Report
Product code 
1094969

Biosimilars Market Size By Product, By Application, By Manufacturer, By Technology Industry Analysis Report, Regional Outlook, Application Potential, COVID-19 Impact Analysis, Competitive Market Share & Forecast, 2022 - 2030

Published: | Global Market Insights Inc. | 650 Pages | Delivery time: 2-3 business days

Price

Back to Top
Biosimilars Market Size By Product, By Application, By Manufacturer, By Technology Industry Analysis Report, Regional Outlook, Application Potential, COVID-19 Impact Analysis, Competitive Market Share & Forecast, 2022 - 2030
Published: June 24, 2022
Global Market Insights Inc.
Content info: 650 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

The global biosimilars market is expected to grow at an exponential rate through 2030 due to increasing demand for biosimilar drugs for saving costs at healthcare facilities.

Recently, key players have been increasingly collaborating with competitors to enhance their business standing, which has improved overall market dynamics. For instance, in February 2022, Biocon Biologics Ltd. (BBL), a Biocon subsidiary, inked an agreement to acquire Viatris Inc.'s biosimilars business in a $3.35 billion deal.

With the acquisition, Biocon Biologics aimed to offer one of the sector's largest and most comprehensive portfolios of commercialized biosimilars with the addition of a variety of commercially available insulins, immunology & oncology biosimilars, and several other biosimilar assets.

The biosimilars market has been bifurcated in terms of product, application, manufacturer, technology, and region.

Based on product, the industry has been divided into recombinant glycosylated proteins and recombinant non-glycosylated proteins. The human growth hormone segment of the recombinant non-glycosylated proteins registered a substantial market valuation of around $2800 million and is slated to expand at a robust CAGR of approximately 15.4% over the review timeline owing to increased biosimilar demand globally.

With respect to application, the biosimilars market has been classified into hematology, oncology, autoimmune disease, growth hormone deficiency, diabetes, and others. The diabetes segment accounted for more than 14.2% of the application market share and is projected to exhibit a positive CAGR of nearly 15.2% over the forecast period attributed to surging prevalence of the disease among the global population.

With regards to manufacturer, the market has been categorized into contract research and manufacturing services and in-house. In 2021, the biosimilars market share from the contract research and manufacturing services segment was worth over $6,900 million and is set to showcase robust growth through 2030. The biosimilars industry's top players manufacture their products in the warehouses they own, which has resulted in the in-house category contributing to over three-fourths of the market size in 2021.

Based on technology, the biosimilars industry has been divided into recombinant DNA technology (rDNA technology) and monoclonal antibodies (MAb) technology. The MAb technology is the most recent and cutting-edge method of producing biosimilars, and as a result, it is foreseen to experience a CAGR of around 13.9% over the forthcoming years.

From the regional standpoint, the North America biosimilars market accounted for more than 28% of the overall industry revenue in 2021 and is set to witness considerable growth through the forecast period pertaining to mounting FDA approvals of biosimilar drugs in the North American region.

Product Code: 3328

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definitions
  • 1.2 Base estimates & working
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Biosimilars industry 360 degree synopsis, 2017-2030 (USD Million)
    • 2.1.1 Business trends
    • 2.1.2 Product trends
    • 2.1.3 Application trends
    • 2.1.4 Manufacturer trends
    • 2.1.5 Technology trends
    • 2.1.6 Regional trends

Chapter 3 Biosimilars Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2017-2030 (USD Million)
  • 3.3 Industry impact factors
    • 3.3.1 Growth drivers
      • 3.3.1.1 Strong product pipeline
      • 3.3.1.2 Rise in prevalence of chronic diseases across the globe
      • 3.3.1.3 Expiry of blockbuster biologics
      • 3.3.1.4 Cost-effectiveness of biosimilars
      • 3.3.1.5 Recent biosimilar product approvals in major countries
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 Availability of alternative medications
      • 3.3.2.2 Regulatory Uncertainty
      • 3.3.2.3 High developmental costs
      • 3.3.2.4 Complex manufacturing process
  • 3.4 Growth potential analysis
    • 3.4.1 By product
    • 3.4.2 By application
    • 3.4.3 By manufacturer
    • 3.4.4 By technology
  • 3.5 COVID-19 impact analysis
  • 3.6 PORTER's Analysis
  • 3.7 Regulatory landscape
    • 3.7.1 U.S.
    • 3.7.2 Canada
    • 3.7.3 Europe
    • 3.7.4 India
    • 3.7.5 Japan
    • 3.7.6 South Korea
    • 3.7.7 Australia
    • 3.7.8 Singapore
  • 3.8 Reimbursement landscape
    • 3.8.1 U.S.
    • 3.8.2 Europe
    • 3.8.3 Canada
    • 3.8.4 Australia
    • 3.8.5 New Zealand
  • 3.9 Market analysis
    • 3.9.1 Strength
    • 3.9.2 Weakness
    • 3.9.3 Opportunity
    • 3.9.4 Threat
  • 3.10 U.S. biosimilars insurance coverage, 2021
  • 3.11 Biosimilar litigation landscape
  • 3.12 Biosimilar product pipeline analysis
    • 3.12.1 Amgen
    • 3.12.2 Biocon
    • 3.12.3 Sandoz
    • 3.12.4 Celltrion
    • 3.12.5 Coherus BioSciences
    • 3.12.6 Fresenius Kabi
    • 3.12.7 Pfizer
    • 3.12.8 Lupin
    • 3.12.9 Samsung Bioepis
    • 3.12.10 Teva Pharmaceuticals
  • 3.13 Biosimilars approval scenario, 2017-2022
    • 3.13.1 U.S.
    • 3.13.2 Canada
    • 3.13.3 Europe
    • 3.13.4 India
    • 3.13.5 South Korea
    • 3.13.6 Australia
    • 3.13.7 New Zealand
    • 3.13.8 Singapore
    • 3.13.9 Malaysia
  • 3.14 Biologics patent expiry scenario
  • 3.15 Biosimilars industry evolution
  • 3.16 Biosimilars factor analysis
    • 3.16.1 Access
    • 3.16.2 Regulations
    • 3.16.3 Payer assessment and access
    • 3.16.4 Physician acceptance
    • 3.16.5 Patient acceptance
    • 3.16.6 Number of biosimilar approvals
  • 3.17 Biosimilars landscape - country analysis
    • 3.17.1 U.S.
    • 3.17.2 Europe
    • 3.17.3 China
    • 3.17.4 Japan
    • 3.17.5 India
    • 3.17.6 South Korea
  • 3.18 Key market success factors
  • 3.19 International policies on use of biosimilar drugs
    • 3.19.1 Interchangeability, Switching and Substitution
    • 3.19.2 Supply Side Policies
    • 3.19.3 Prescribing Incentives
  • 3.20 Competitive landscape, 2021
    • 3.20.1 Competitive matrix analysis, 2021
  • 3.21 PESTEL analysis

Chapter 4 Biosimilars Market, By Product

  • 4.1 Key segment trends
  • 4.2 Recombinant Non-Glycosylated Proteins
    • 4.2.1 Market size, by region, 2017-2030 (USD Million)
    • 4.2.2 Human Growth Hormone
      • 4.2.2.1 Market size, by region, 2017-2030 (USD Million)
    • 4.2.3 Granulocyte Colony-Stimulating Factor (Filgrastim)
      • 4.2.3.1 Market size, by region, 2017-2030 (USD Million)
    • 4.2.4 Insulin
      • 4.2.4.1 Market size, by region, 2017-2030 (USD Million)
    • 4.2.5 Interferon
      • 4.2.5.1 Market size, by region, 2017-2030 (USD Million)
      • 4.2.5.2 Alfa
        • 4.2.5.2.1 Market size, by region, 2017-2030 (USD Million)
      • 4.2.5.3 Beta
        • 4.2.5.3.1 Market size, by region, 2017-2030 (USD Million)
  • 4.3 Recombinant Glycosylated Proteins
    • 4.3.1 Market size, by region, 2017-2030 (USD Million)
    • 4.3.2 Erythropoietin
      • 4.3.2.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.2.2 Alfa
        • 4.3.2.2.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.2.3 Zeta
        • 4.3.2.3.1 Market size, by region, 2017-2030 (USD Million)
    • 4.3.3 Monoclonal Antibodies
      • 4.3.3.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.3.2 Infliximab
        • 4.3.3.2.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.3.3 Rituximab
        • 4.3.3.3.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.3.4 Adalimumab
        • 4.3.3.4.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.3.5 Trastuzumab
        • 4.3.3.5.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.3.6 Bevacizumab
        • 4.3.3.6.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.3.7 Etanercept
        • 4.3.3.7.1 Market size, by region, 2017-2030 (USD Million)
    • 4.3.4 Follitropin
      • 4.3.4.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.4.2 Alfa
        • 4.3.4.2.1 Market size, by region, 2017-2030 (USD Million)
      • 4.3.4.3 Beta
        • 4.3.4.3.1 Market size, by region, 2017-2030 (USD Million)
    • 4.3.5 Low Molecular Weight Heparin (LMWHs)
      • 4.3.5.1 Market size, by region, 2017-2030 (USD Million)

Chapter 5 Biosimilars Market, By Application

  • 5.1 Key segment trends
  • 5.2 Hematology
    • 5.2.1 Market size, by region, 2017-2030 (USD Million)
    • 5.2.2 Neutropenia
      • 5.2.2.1 Market size, by region, 2017-2030 (USD Million)
    • 5.2.3 Anemia
      • 5.2.3.1 Market size, by region, 2017-2030 (USD Million)
    • 5.2.4 Others
      • 5.2.4.1 Market size, by region, 2017-2030 (USD Million)
  • 5.3 Oncology
    • 5.3.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.2 Lung Cancer
      • 5.3.2.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.3 Brain Cancer
      • 5.3.3.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.4 Breast Cancer
      • 5.3.4.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.5 Cervical Cancer
      • 5.3.5.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.6 Colorectal Cancer
      • 5.3.6.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.7 Leukemia
      • 5.3.7.1 Market size, by region, 2017-2030 (USD Million)
      • 5.3.7.2 Non-Hodgkin Lymphoma (NHL)
        • 5.3.7.2.1 Market size, by region, 2017-2030 (USD Million)
      • 5.3.7.3 Chronic Lymphocytic Leukemia (CLL)
        • 5.3.7.3.1 Market size, by region, 2017-2030 (USD Million)
      • 5.3.7.4 Others
        • 5.3.7.4.1 Market size, by region, 2017-2030 (USD Million)
    • 5.3.8 Others
      • 5.3.8.1 Market size, by region, 2017-2030 (USD Million)
  • 5.4 Autoimmune Disease
    • 5.4.1 Market size, by region, 2017-2030 (USD Million)
    • 5.4.2 Arthritis
      • 5.4.2.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.2.2 Rheumatoid Arthritis
        • 5.4.2.2.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.2.3 Psoriatic Arthritis
        • 5.4.2.3.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.2.4 Juvenile Arthritis
        • 5.4.2.4.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.2.5 Ankylosing Spondylitis
        • 5.4.2.5.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.2.6 Others
        • 5.4.2.6.1 Market size, by region, 2017-2030 (USD Million)
    • 5.4.3 Inflammatory Bowel Disease (IBD)
      • 5.4.3.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.3.2 Ulcerative Colitis
        • 5.4.3.2.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.3.3 Crohn's Disease
        • 5.4.3.3.1 Market size, by region, 2017-2030 (USD Million)
      • 5.4.3.4 Others
        • 5.4.3.4.1 Market size, by region, 2017-2030 (USD Million)
    • 5.4.4 Psoriasis
      • 5.4.4.1 Market size, by region, 2017-2030 (USD Million)
    • 5.4.5 Others
      • 5.4.5.1 Market size, by region, 2017-2030 (USD Million)
  • 5.5 Growth Hormone Deficiency
    • 5.5.1 Market size, by region, 2017-2030 (USD Million)
  • 5.6 Diabetes
    • 5.6.1 Market size, by region, 2017-2030 (USD Million)
  • 5.7 Others
    • 5.7.1 Market size, by region, 2017-2030 (USD Million)

Chapter 6 Biosimilars Market, By Manufacturer

  • 6.1 Key segment trends
  • 6.2 Contract Research and Manufacturing Services
    • 6.2.1 Market size, by region, 2017-2030 (USD Million)
  • 6.3 In-house
    • 6.3.1 Market size, by region, 2017-2030 (USD Million)

Chapter 7 Biosimilars Market, By Technology

  • 7.1 Key segment trends
  • 7.2 Recombinant DNA Technology (rDNA technology)
    • 7.2.1 Market size, by region, 2017-2030 (USD Million)
  • 7.3 Monoclonal Antibodies (MAb) Technology
    • 7.3.1 Market size, by region, 2017-2030 (USD Million)

Chapter 8 Biosimilars Market, By Region

  • 8.1 Key regional trends
  • 8.2 North America
    • 8.2.1 Market size, by country, 2017-2030 (USD Million)
    • 8.2.2 Market size, by product, 2017-2030 (USD Million)
      • 8.2.2.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
      • 8.2.2.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.2.2.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
    • 8.2.3 Market size, by application, 2017-2030 (USD Million)
      • 8.2.3.1 Market size, by hematology, 2017-2030 (USD Million)
      • 8.2.3.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.2.3.2.1 Market size, by leukemia, 2017-2030 (USD Million)
      • 8.2.3.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.2.3.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.2.3.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
    • 8.2.4 Market size, by manufacturer, 2017-2030 (USD Million)
    • 8.2.5 Market size, by technology, 2017-2030 (USD Million)
    • 8.2.6 U.S.
      • 8.2.6.1 Market size, by product, 2017-2030 (USD Million)
        • 8.2.6.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.2.6.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.2.6.1.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
      • 8.2.6.2 Market size, by application, 2017-2030 (USD Million)
        • 8.2.6.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.2.6.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.2.6.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.2.6.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.2.6.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.2.6.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.2.6.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.2.6.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.2.7 Canada
      • 8.2.7.1 Market size, by product, 2017-2030 (USD Million)
        • 8.2.7.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.2.7.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.2.7.1.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
      • 8.2.7.2 Market size, by application, 2017-2030 (USD Million)
        • 8.2.7.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.2.7.2.2 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.2.7.2.2.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.2.7.2.2.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.2.7.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.2.7.4 Market size, by technology, 2017-2030 (USD Million)
  • 8.3 Europe
    • 8.3.1 Market size, by country, 2017-2030 (USD Million)
    • 8.3.2 Market size, by product, 2017-2030 (USD Million)
      • 8.3.2.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.2.1.1 Market size, by interferon, 2017-2030 (USD Million)
      • 8.3.2.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.2.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.2.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.2.2.3 Market size, by follitropin, 2017-2030 (USD Million)
    • 8.3.3 Market size, by application, 2017-2030 (USD Million)
      • 8.3.3.1 Market size, by hematology, 2017-2030 (USD Million)
      • 8.3.3.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.3.2.1 Market size, by leukemia, 2017-2030 (USD Million)
      • 8.3.3.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.3.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.3.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
    • 8.3.4 Market size, by manufacturer, 2017-2030 (USD Million)
    • 8.3.5 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.6 Germany
      • 8.3.6.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.6.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.6.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.6.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.6.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.6.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.6.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.6.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.6.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.6.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.6.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.6.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.6.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.6.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.6.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.6.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.7 UK
      • 8.3.7.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.7.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.7.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.7.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.7.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.7.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.7.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.7.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.7.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.7.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.7.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.7.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.7.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.7.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.7.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.7.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.8 France
      • 8.3.8.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.8.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.8.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.8.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.8.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.8.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.8.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.8.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.8.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.8.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.8.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.8.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.8.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.8.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.8.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.8.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.9 Spain
      • 8.3.9.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.9.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.9.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.9.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.9.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.9.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.9.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.9.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.9.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.9.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.9.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.9.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.9.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.9.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.9.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.9.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.10 Italy
      • 8.3.10.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.10.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.10.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.10.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.10.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.10.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.10.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.10.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.10.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.10.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.10.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.10.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.10.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.10.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.10.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.10.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.11 Turkey
      • 8.3.11.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.11.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.11.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.11.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.11.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.11.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.11.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.11.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.11.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.11.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.11.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.11.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.11.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.11.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.11.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.11.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.12 Austria
      • 8.3.12.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.12.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.12.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.12.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.12.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.12.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.12.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.12.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.12.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.12.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.12.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.12.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.12.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.12.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.12.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.12.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.13 Belgium
      • 8.3.13.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.13.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.13.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.13.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.13.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.13.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.13.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.13.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.13.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.13.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.13.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.13.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.13.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.13.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.13.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.13.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.14 Bulgaria
      • 8.3.14.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.14.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.14.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.14.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.14.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.14.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.14.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.14.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.14.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.14.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.14.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.14.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.14.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.14.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.14.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.14.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.15 Czech Republic
      • 8.3.15.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.15.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.15.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.15.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.15.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.15.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.15.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.15.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.15.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.15.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.15.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.15.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.15.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.15.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.15.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.15.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.16 Denmark
      • 8.3.16.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.16.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.16.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.16.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.16.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.16.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.16.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.16.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.16.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.16.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.16.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.16.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.16.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.16.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.16.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.16.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.17 Finland
      • 8.3.17.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.17.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.17.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.17.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.17.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.17.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.17.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.17.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.17.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.17.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.17.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.17.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.17.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.17.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.17.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.17.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.18 Greece
      • 8.3.18.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.18.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.18.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.18.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.18.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.18.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.18.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.18.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.18.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.18.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.18.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.18.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.18.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.18.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.18.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.18.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.19 Hungary
      • 8.3.19.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.19.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.19.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.19.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.19.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.19.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.19.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.19.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.19.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.19.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.19.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.19.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.19.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.19.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.19.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.19.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.20 Ireland
      • 8.3.20.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.20.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.20.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.20.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.20.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.20.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.20.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.20.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.20.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.20.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.20.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.20.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.20.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.20.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.20.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.20.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.21 Netherlands
      • 8.3.21.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.21.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.21.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.21.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.21.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.21.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.21.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.21.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.21.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.21.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.21.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.21.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.21.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.21.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.21.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.21.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.22 Norway
      • 8.3.22.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.22.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.22.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.22.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.22.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.22.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.22.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.22.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.22.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.22.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.22.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.22.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.22.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.22.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.22.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.22.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.23 Romania
      • 8.3.23.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.23.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.23.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.23.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.23.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.23.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.23.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.23.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.23.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.23.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.23.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.23.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.23.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.23.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.23.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.23.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.24 Slovakia
      • 8.3.24.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.24.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.24.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.24.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.24.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.24.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.24.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.24.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.24.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.24.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.24.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.24.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.24.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.24.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.24.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.24.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.25 Slovenia
      • 8.3.25.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.25.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.25.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.25.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.25.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.25.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.25.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.25.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.25.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.25.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.25.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.25.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.25.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.25.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.25.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.25.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.26 Sweden
      • 8.3.26.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.26.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.26.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.26.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.26.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.26.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.26.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.26.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.26.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.26.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.26.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.26.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.26.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.26.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.26.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.26.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.3.27 Switzerland
      • 8.3.27.1 Market size, by product, 2017-2030 (USD Million)
        • 8.3.27.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.27.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.3.27.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.3.27.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.3.27.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.3.27.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.3.27.2 Market size, by application, 2017-2030 (USD Million)
        • 8.3.27.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.3.27.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.3.27.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.3.27.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.3.27.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.3.27.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.3.27.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.3.27.4 Market size, by technology, 2017-2030 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Market size, by country, 2017-2030 (USD Million)
    • 8.4.2 Market size, by product, 2017-2030 (USD Million)
      • 8.4.2.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.2.1.1 Market size, by interferon, 2017-2030 (USD Million)
      • 8.4.2.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.2.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.4.2.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.4.2.2.3 Market size, by follitropin, 2017-2030 (USD Million)
    • 8.4.3 Market size, by application, 2017-2030 (USD Million)
      • 8.4.3.1 Market size, by hematology, 2017-2030 (USD Million)
      • 8.4.3.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.3.2.1 Market size, by leukemia, 2017-2030 (USD Million)
      • 8.4.3.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.4.3.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.4.3.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
    • 8.4.4 Market size, by manufacturer, 2017-2030 (USD Million)
    • 8.4.5 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.6 China
      • 8.4.6.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.6.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.6.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.4.6.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.6.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.4.6.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.4.6.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.4.6.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.6.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.4.6.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.6.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.4.6.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.4.6.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.4.6.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.4.6.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.6.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.7 Japan
      • 8.4.7.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.7.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.7.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.7.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.4.7.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
      • 8.4.7.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.7.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.4.7.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.7.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.4.7.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.4.7.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.4.7.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.4.7.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.7.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.8 India
      • 8.4.8.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.8.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.8.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
        • 8.4.8.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.8.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.4.8.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.4.8.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.4.8.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.8.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.4.8.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.8.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.4.8.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.4.8.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.4.8.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.4.8.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.8.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.9 South Korea
      • 8.4.9.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.9.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.9.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.9.1.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
      • 8.4.9.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.9.2.1 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.9.2.1.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.4.9.2.2 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.4.9.2.2.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.4.9.2.2.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.4.9.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.9.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.10 Australia
      • 8.4.10.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.10.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.10.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.10.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
        • 8.4.10.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
        • 8.4.10.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
      • 8.4.10.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.10.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.4.10.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.10.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
        • 8.4.10.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.4.10.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.4.10.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.4.10.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.10.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.11 New Zealand
      • 8.4.11.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.11.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.11.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.11.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
      • 8.4.11.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.11.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.4.11.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.11.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
      • 8.4.11.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.11.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.12 Singapore
      • 8.4.12.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.12.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.12.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.12.1.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
      • 8.4.12.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.12.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.4.12.2.2 Market size, by autoimmune disease, 2017-2030 (USD Million)
        • 8.4.12.2.2.1 Market size, by arthritis, 2017-2030 (USD Million)
        • 8.4.12.2.2.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
      • 8.4.12.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.12.4 Market size, by technology, 2017-2030 (USD Million)
    • 8.4.13 Malaysia
      • 8.4.13.1 Market size, by product, 2017-2030 (USD Million)
        • 8.4.13.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.13.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
        • 8.4.13.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
      • 8.4.13.2 Market size, by application, 2017-2030 (USD Million)
        • 8.4.13.2.1 Market size, by hematology, 2017-2030 (USD Million)
        • 8.4.13.2.2 Market size, by oncology, 2017-2030 (USD Million)
        • 8.4.13.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
      • 8.4.13.3 Market size, by manufacturer, 2017-2030 (USD Million)
      • 8.4.13.4 Market size, by technology, 2017-2030 (USD Million)

Chapter 9 Company Profiles

  • 9.1 Competitive dashboard, 2021
  • 9.2 Biocon Ltd
    • 9.2.1 Business overview
    • 9.2.2 Financial data
    • 9.2.3 Product landscape
    • 9.2.4 Strategic outlook
    • 9.2.5 SWOT analysis
  • 9.3 Sandoz
    • 9.3.1 Business overview
    • 9.3.2 Financial data
    • 9.3.3 Product landscape
    • 9.3.4 Strategic outlook
    • 9.3.5 SWOT analysis
  • 9.4 Viatris
    • 9.4.1 Business overview
    • 9.4.2 Financial data
    • 9.4.3 Product landscape
    • 9.4.4 Strategic outlook
    • 9.4.5 SWOT analysis
  • 9.5 Bio-Thera Solutions
    • 9.5.1 Business overview
    • 9.5.2 Financial data
    • 9.5.3 Product landscape
    • 9.5.4 Strategic outlook
    • 9.5.5 SWOT analysis
  • 9.6 Pfizer
    • 9.6.1 Business overview
    • 9.6.2 Financial data
    • 9.6.3 Product landscape
    • 9.6.4 Strategic outlook
    • 9.6.5 SWOT analysis
  • 9.7 Dr. Reddy's Laboratories
    • 9.7.1 Business overview
    • 9.7.2 Financial data
    • 9.7.3 Product landscape
    • 9.7.4 Strategic outlook
    • 9.7.5 SWOT analysis
  • 9.8 Amgen Inc.
    • 9.8.1 Business overview
    • 9.8.2 Financial data
    • 9.8.3 Product landscape
    • 9.8.4 Strategic outlook
    • 9.8.5 SWOT analysis
  • 9.9 Teva Pharmaceuticals
    • 9.9.1 Business overview
    • 9.9.2 Financial data
    • 9.9.3 Product landscape
    • 9.9.4 Strategic outlook
    • 9.9.5 SWOT analysis
  • 9.10 Fresenius Kabi
    • 9.10.1 Business overview
    • 9.10.2 Financial data
    • 9.10.3 Product landscape
    • 9.10.4 Strategic outlook
    • 9.10.5 SWOT analysis
  • 9.11 Coherus Biosciences
    • 9.11.1 Business overview
    • 9.11.2 Financial data
    • 9.11.3 Product landscape
    • 9.11.4 Strategic outlook
    • 9.11.5 SWOT analysis
  • 9.12 Apobiologix
    • 9.12.1 Business overview
    • 9.12.2 Financial data
    • 9.12.3 Product landscape
    • 9.12.4 Strategic outlook
    • 9.12.5 SWOT analysis
  • 9.13 Biocad
    • 9.13.1 Business overview
    • 9.13.2 Financial data
    • 9.13.3 Product landscape
    • 9.13.4 Strategic outlook
    • 9.13.5 SWOT analysis
  • 9.14 Intas Pharma
    • 9.14.1 Business overview
    • 9.14.2 Financial data
    • 9.14.3 Product landscape
    • 9.14.4 Strategic outlook
    • 9.14.5 SWOT analysis
  • 9.15 Reliance Life Sciences
    • 9.15.1 Business overview
    • 9.15.2 Financial data
    • 9.15.3 Product landscape
    • 9.15.4 Strategic outlook
    • 9.15.5 SWOT analysis
  • 9.16 Celltrion
    • 9.16.1 Business overview
    • 9.16.2 Financial data
    • 9.16.3 Product landscape
    • 9.16.4 Strategic outlook
    • 9.16.5 SWOT analysis
  • 9.17 Zydus Cadila
    • 9.17.1 Business overview
    • 9.17.2 Financial data
    • 9.17.3 Product landscape
    • 9.17.4 Strategic outlook
    • 9.17.5 SWOT analysis
  • 9.18 Lupin Pharma
    • 9.18.1 Business overview
    • 9.18.2 Financial data
    • 9.18.3 Product landscape
    • 9.18.4 Strategic outlook
    • 9.18.5 SWOT analysis
  • 9.19 Samsung Bioepis
    • 9.19.1 Business overview
    • 9.19.2 Financial data
    • 9.19.3 Product landscape
    • 9.19.4 Strategic outlook
    • 9.19.5 SWOT analysis